Artelo Biosciences, Inc. SEC filings ARTL
Artelo Biosciences, Inc. has 465 filings in SEC EDGAR's recent list, going back to Oct 8, 2014. Its latest annual report, Form ARS, was filed on Jun 5, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 9, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| PRER14A | Prer 14a | Jun 22, 2026 | — |
| EFFECT | Filing | May 19, 2026 | — |
| CORRESP | Letter to the SEC | May 15, 2026 | — |
| UPLOAD | Letter from the SEC | May 11, 2026 | — |
| EFFECT | Filing | Apr 15, 2026 | — |
| CORRESP | Letter to the SEC | Apr 13, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 13, 2026 | — |
| D | Filing | Apr 6, 2026 | — |
| EFFECT | Filing | Mar 30, 2026 | — |
| D | Filing | Mar 27, 2026 | — |
| D | Filing | Mar 27, 2026 | — |
| D | Filing | Mar 27, 2026 | — |
| RW | Form rw | Mar 27, 2026 | — |
| EFFECT | Filing | Mar 25, 2026 | — |
| CORRESP | Letter to the SEC | Mar 25, 2026 | — |
| CORRESP | Letter to the SEC | Mar 20, 2026 | — |
| CORRESP | Letter to the SEC | Mar 20, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 13, 2026 | — |
| DRS | Filing | Mar 9, 2026 | — |
| D | Filing | Feb 6, 2026 | — |
| EFFECT | Filing | Dec 2, 2025 | — |
| CORRESP | Letter to the SEC | Dec 1, 2025 | — |
| D | Filing | Nov 10, 2025 | — |
| DRS | Filing | Sep 29, 2025 | — |
| D | Filing | Aug 13, 2025 | — |
| EFFECT | Filing | Jul 17, 2025 | — |
| CORRESP | Letter to the SEC | Jul 16, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2025 | — |
| D | Filing | Jul 9, 2025 | — |
| 25-NSE | Delisting notice | Jun 17, 2024 | — |
| EFFECT | Filing | Jul 14, 2023 | — |
| CORRESP | Letter to the SEC | Jul 12, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 10, 2023 | — |
| DEL AM | Filing | Jul 7, 2023 | — |
| EFFECT | Filing | May 31, 2022 | — |
| CORRESP | Letter to the SEC | May 26, 2022 | — |
| UPLOAD | Letter from the SEC | May 26, 2022 | — |
| D | Filing | May 20, 2022 | — |
| EFFECT | Filing | Jan 21, 2021 | — |
| EFFECT | Filing | Jan 21, 2021 | — |
| EFFECT | Filing | Oct 8, 2020 | — |
| CORRESP | Letter to the SEC | Oct 7, 2020 | — |
| CORRESP | Letter to the SEC | Oct 7, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 2, 2020 | — |
| D | Filing | May 18, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 22, 2020 | — |
| CORRESP | Letter to the SEC | Apr 21, 2020 | — |
| EFFECT | Filing | Apr 10, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2020 | — |
| CORRESP | Letter to the SEC | Mar 27, 2020 | — |
| UPLOAD | Letter from the SEC | Mar 23, 2020 | — |
| EFFECT | Filing | Feb 3, 2020 | — |
| CORRESP | Letter to the SEC | Feb 3, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 21, 2020 | — |
| EFFECT | Filing | Dec 20, 2019 | — |
| EFFECT | Filing | Dec 20, 2019 | — |
| CORRESP | Letter to the SEC | Dec 19, 2019 | — |
| CORRESP | Letter to the SEC | Dec 19, 2019 | — |
| CORRESP | Letter to the SEC | Nov 12, 2019 | — |
| CORRESP | Letter to the SEC | Nov 8, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 8, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 31, 2019 | — |
| CERT | Filing | Jun 21, 2019 | — |
| 8-A12B | Filing | Jun 21, 2019 | — |
| EFFECT | Filing | Jun 20, 2019 | — |
| CORRESP | Letter to the SEC | Jun 20, 2019 | — |
| CORRESP | Letter to the SEC | Jun 20, 2019 | — |
| D | Filing | Jun 4, 2019 | — |
| D | Filing | Jun 4, 2019 | — |
| EFFECT | Filing | Oct 5, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 4, 2018 | — |
| CORRESP | Letter to the SEC | Oct 3, 2018 | — |
| D | Filing | Sep 14, 2018 | — |
| CT ORDER | Filing | May 30, 2018 | — |
| CT ORDER | Filing | May 30, 2018 | — |
| EFFECT | Filing | May 29, 2018 | — |
| CORRESP | Letter to the SEC | May 25, 2018 | — |
| UPLOAD | Letter from the SEC | May 1, 2018 | — |
| D | Filing | Apr 6, 2018 | — |
| UPLOAD | Letter from the SEC | Mar 27, 2018 | — |
| UPLOAD | Letter from the SEC | Feb 27, 2018 | — |
| NT 10-Q | Filing | Jul 18, 2017 | May 31, 2017 |
| CT ORDER | Filing | Jul 17, 2017 | — |
| D | Filing | Jun 5, 2017 | — |
| NT 10-K | Form 12b-25 | Nov 30, 2015 | Aug 31, 2015 |
| EFFECT | Filing | Jan 28, 2015 | — |
| CORRESP | Letter to the SEC | Jan 23, 2015 | — |
| UPLOAD | Letter from the SEC | Nov 3, 2014 | — |
Showing 88 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ARTL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Solana Beach, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1621221
- Former names
- REACTIVE MEDICAL INC. (until Apr 17, 2017); KNIGHT KNOX DEVELOPMENT CORP. (until Feb 6, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.